Patents are unique in that they are a form of IP protection established in the U.S. Constitution that grants inventors the right to their inventions without others being able to make, use or sell them for a set period of time. Many essential industries rely on the U.S. patent system to foster innovation, and the existence of a patent doesn’t necessarily prevent others from developing and patenting different solutions to the same problem. And once the patent has expired, the invention can be freely used by anyone.
For the biopharmaceutical industry, the U.S. patent system provides critical incentives for innovation and fuels the creation of new lifesaving treatments and cures for patients. In fact, patents touch nearly every facet of biopharmaceutical innovation from initial drug discovery to new uses identified after Food and Drug Administration (FDA) approval, and most medicines are associated with multiple patents.
As medical innovation transforms to target more complex diseases and as genomics and personalized medicines are pursued, manufacturing processes are also becoming more complicated. In today’s IP Explained, we are taking a closer look at four key forms of patent protections and how each plays an important and unique role in supporting innovation throughout the biopharmaceutical lifecycle.
- Active ingredient or component patents protect the biologically active component of a drug.
- Drug product patents refer to the particular state in which the medicine is delivered to the patient, such as the formulation or dosage form. New dosage forms for FDA-approved medicines, such as when an injectable drug can be taken as a pill instead, can improve patient adherence to treatments, ensure proper dosage, and improve quality of life for patients. As a result, these innovations may lead to improved health outcomes and a reduction in hospitalizations.
- Methods of manufacturing patents cover the complex process or steps required to manufacture a medicine. Such advances can improve the safety, efficacy and quality of other types of medicines
- Methods of use patents protect the use of a medicine to treat a particular disease. Innovations to medicines continue well after their active ingredients are patented and the medicines are approved by the FDA. This ongoing research can result in approvals for new uses in different patient populations, conditions or disease states. For example, medicines initially developed to treat rheumatoid arthritis have been shown to help treat other autoimmune conditions, including Crohn’s disease and ulcerative colitis. New uses give patients new, and frequently better, options to treat their illnesses.
Each of these forms of medical advancements plays a critical role in improving the lives of patients and has the potential to increase adherence, improve health outcomes and reduce unnecessary hospitalizations. By protecting all forms of biopharmaceutical innovation, we can continue to improve the lives of patients and keep the U.S. as the global leader in biopharmaceutical research and development.
Follow our IP Explained series to learn more about how patents enable a healthier future for patients.
Tom Wilbur
Tom Wilbur is Deputy Vice President of Public Affairs at PhRMA where he leads the state public affairs team and Voters for Cures, PhRMA’s grassroots advocacy initiative. Prior to joining PhRMA in 2019, Tom served as a senior aide on Capitol Hill for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom holds an M.A. in strategic communications from Michigan State University and a B.A. in social science and history from Central Michigan University. He enjoys spending time with family and friends, volunteering, reading and golfing.
Updated Analysis Underscores the Need for Brazil to Address Patent Backlogs
How post-approval innovation keeps delivering for patients
40 Years of Hatch-Waxman: How Can We Secure its Legacy?
40 Years of Hatch-Waxman: How does the Hatch-Waxman Act help patients?
40 Years of Hatch-Waxman: What is the Hatch-Waxman Act?
Biden Administration report debunks myths around patent “evergreening” and “thickets”
What to know about the latest effort to break patents using a legally dubious avenue
WTAS: Proposed Unsubstantiated USPTO Rule Change is a Threat to American Innovation
PhRMA launches education campaign on the benefits of America's IP system
Experts discuss the value of IP at Senate Judiciary Committee hearing
The impact of innovative medicines: A caregiver's perspective
Proposed march-in framework would chill American innovation
The White House continues to attack American innovation
It’s PBMs, not patents, blocking competition
New PhRMA site demonstrates how a technology-driven health care system brings benefits to patients
PhRMA submits comments to USPTO highlighting important role of patent system in medicine development
Six ways I-MAK is lying about biopharma patents
New report ignores benefits of patent system to innovation and patients
The dangers of expanding the TRIPS waiver
Patent policy changes proposed by USPTO and FDA would leave patients behind
Legislation threatens patent protections and future innovation
Patients and innovators lose if the government pursues ‘march-in’
IP Explained: How does the U.S. patent process work?
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
The Biden Administration allows politics to upend a pragmatic pandemic response
The latest: What they are saying: Intellectual property protections vital to COVID-19 research, development and manufacturing
New video: See how strong IP protections lead to stronger treatments for patients
Why the U.S. biopharmaceutical industry is leading the charge against COVID-19
The latest: What they are saying: intellectual property protections critical as we work to defeat COVID-19
The latest: What they are saying: Importance of intellectual property protections to combat COVID-19
The latest: What they are saying: Intellectual property protections critical as we work to defeat COVID-19
IP Explained: Intellectual property system working to combat COVID-19
What they are saying: Intellectual property protections are critical as we work to defeat COVID-19
The continued imperative to protect U.S. innovation worldwide
IP Explained: Four key takeaways from new Bayh-Dole white paper
IP Explained: By the Numbers: How reliable IP protections promote a strong U.S. economy
IP Explained: FACT CHECK: March-In Authority and the Bayh-Dole Act
IP Explained: Four things to know about the Bayh-Dole Act
IP Explained: Three forms of IP protections for medicines
IP Explained: Understanding biopharmaceutical innovation
IP Explained: Why IP protections are important for biologic medicines
IP Explained: What is Section 101 and why reforms are needed
IP Explained: How Hatch-Waxman successfully balances affordability and innovation
IP Explained: Myth vs. fact about strong patent protections in the biopharmaceutical industry
IP Explained: What they are saying on the importance of strong intellectual property protections
IP Explained: Why patents are so critical to biopharmaceutical innovation
New report: Using march-in authority would jeopardize U.S. innovation
Special 301 submission calls for a level playing field for American innovators
Celebrating U.S. innovation as USPTO issues the 10 millionth patent
Supreme Court decisions in two cases pave way for IPR reforms
What is inter partes review and why does it matter?
ICYMI: Ubl weighs in on how fair trade protects US biopharmaceutical innovation
Illegal trade barriers discriminate against U.S. innovators
New nonprofit – I-ACT for Children – launches to promote innovative medicines development for young patients in need
PhRMA urges USTR to protect American innovators abroad
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
Patents
IP Explained
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle
IP Explained: How patents support innovation throughout the biopharmaceutical lifecycle